FGFR1 also undergoes gene amplification and translocation, particularly in the luminal B subtype of BC (6) . In addition to gene amplification, transcriptional expression of FGFR1-iiic is dramatically increased by epithelial-mesenchymal transition (EMT) (1, 7, 8) . We recently demonstrated that FGFR1 is a unique marker of EMT as its expression remains elevated through the oncogenic reversion of this process, or mesenchymal-epithelial transition (MET) (1) . This is a key finding as highly aggressive BC cells can readily transition between epithelial and mesenchymal states (9, 10) . Therefore, the maintained upregulation of FGFR1 during epithelialmesenchymal plasticity contributes to the potential of this growth factor signaling pathway as a therapeutic target for the treatment of metastatic BC. However, it remained to be determined whether enhanced FGFR expression alone is sufficient to drive FGF-mediated metastatic tumor growth or if other aspects of EMT are also required for this process.
In addition to modulated expression of growth factor receptors, another critical aspect of EMT is the production of extracellular matrix proteins and their cognate sensing molecules (11) . Along these lines, EMT-mediated upregulation of αvβ3 integrin is well established, as is its ability to interact with TGF-β receptors and epidermal growth factor receptor (EGFR) (12, 13) .
Furthermore, biochemical studies and results from endothelial cells suggest that β3 integrin also can bind to FGFs and may form a ternary complex with FGF and FGFR1 (14, 15, 16) . Given these previous findings, we hypothesized that β3 integrin and FGFR1 work in concert during EMT to promote the metastatic progression of BC.
To date, nearly all clinically used kinase inhibitors are ATP-competitive, non-covalent compounds whose pharmacodynamics are limited by competition with the large intracellular pool of ATP (17) . The recent FDA approval and clinical success of the covalent EGFR inhibitor Osimertinib for the treatment of lung cancer and the BTK inhibitor Ibrutinib for the treatment of B-cell-derived tumors serves as a proof-of-principle for the continued development of covalent kinase inhibitors as anti-cancer therapeutics (18) . We recently developed FIIN-2, a potent and selective covalent pan-FGFR targeting agent that inhibits FGFR1 in biochemical and cellular assays at nanomolar concentrations (19) . Despite being very potent in cellular assays, FIIN-2 proved not to be a suitable in vivo drug candidate. Therefore, a major objective of the current study was to develop and conduct preclinical, in vivo validation of FINN-4, our newly formulated covalent inhibitor of FGFR. Taken together, our studies present mechanistic insight into how EMT as a process contributes to FGFR signaling in metastatic BC. Moreover, our findings suggest that β3 integrin, FAK and FGFR can serve as useful biomarkers for the application of our next-generation, covalent inhibitor of FGFR for the treatment of metastatic BC.
Materials and Methods:
Cell lines and Reagents. Murine D2.A1 were obtained from Dr. in 2008. Bioluminescent 4T1 and D2.A1, cells were engineered to stably express firefly luciferase under the selection of Zeocin as previously described (20) . All cell lines were tested and verified via the IMPACT III analysis at IDEXX Bioresearch on April 2, 2014. NMuMG cells expressing Twist and β3 integrin were constructed via stable transduction using pBabe and pMSCV viral particles, respectively. Plasmids encoding the FGFR1-eGFP fusion protein were a kind gift from Michael Stachowiak (Department of Chemistry, State University, Buffalo, NY).
Cellular depletion of β1 and β3 integrin expression was achieved by lentiviral transduction of previously verified pLKO.1 shRNA vectors (Thermo Scientific, Table S1) as described (21) .
Ectopic expression of FGFR1-α-IIIc was accomplished as previously described and selected for using Neomycin (1) . The covalent FGFR inhibitor FIIN-2 was synthesized as described previously (19) . Transfer of tumor tissues was conducted under IRB approval from both HCI and Purdue
University. Approximately 1mm 3 pieces of tumor tissue were engrafted onto the mammary fat pads of NSG mice according to published procedures (22) . Cohorts of these tumor-bearing mice were treated with FIIN-4 (25 mg/kg) every 48 hours. Mammary tumor sizes were measured using digital calipers and the following equation was used to approximate tumor volume (V=(length^2)*(width)*(0.5)). In separate experiments mice were inoculated via the tail vein with ex-vivo 4T1-L4 pulmonary metastases. These pulmonary tumor-bearing mice were similarly treated with FIIN-4. In both cases FIIN-4 was originally suspended in DMSO and then further Immuno assays. For signaling assays cells were serum deprived for 6 hours (NMuMG) or overnight (D2.A1) in the presence or absence of the indicated inhibitors and cells were subsequently stimulated with the indicated growth factors. For immunoblot assays, lysates generated from 2D-and 3D-cultures were prepared as described previously (23) . Antibodies used herein are described in the Supplementary Table S2 . For immunocytochemistry, cells were fixed in 4% formalin, blocked and stained with the indicated antibodies (Table S2 ). For GFPTrap experiments (GFP-Trap_A, ChromoTek), cells were rinsed in 1% formaldehyde, lysed in 1 mL membrane co-IP buffer (50mM TRIS, 15mM EGTA, 100mM NaCl, 0.1% Triton X-100, pH 7.5, and protease inhibitor cocktail (Sigma) added just before use), and 20 μL of supernatant was saved for input control. IHC images of FGFR1 in patient tumors were gathered from the human protein atlas (24, 25) . mRNA transcript analyses. For real-time PCR analysis, NMuMG cells were stimulated with TGF-β1 (5 ng/ml) for 48 hours, at which point total RNA was isolated using RNeasy Plus Kit (Qiagen). Alternatively, RNA was similarly isolated from 4T1 in vitro cultured cells or ex vivo lung metastases. Afterward, total RNA was reverse transcribed using the iScript cDNA Synthesis System (BioRad), and semi-quantitative real-time PCR was conducted using iQ SYBR Green (BioRad) as described previously (23) . For identification of the FGFR splice variants PCR products were visualized by gel electrophoresis. The oligonucleotide primer pairs used have been previously described (1). . Cultrex cushions were supplemented with fibronectin or Collagen I where indicated. Longitudinal bioluminescent growth assays were performed as described (1, 23, 27 Statistical analyses. Statistical values were defined using an unpaired Student's T-test, where a P value < 0.05 was considered significant. Statistically significant differences in the overall survival of 4T1-pulmonary tumor bearing mice were analyzed using a log-rank test and a two-way ANOVA test. P values for all experiments are indicated.
Results

Twist-mediated induction of EMT enhances FGFR signaling in mammary epithelial cells
We and others have previously demonstrated that FGFR1 is upregulated during the process of TGF-β1-induced EMT (Fig 1A; 1,8 ). Consistent with these findings pretreatment with TGF-β1 facilitates FGF2-mediated phosphorylation of Erk1/2 ( Erk1/2 (Fig. 1D ). These findings demonstrate that EMT events that include enhanced FGFR1 expression can facilitate a differential response to subsequent FGF2 ligand stimulation.
β3 integrin redistributes FGFR1 and promotes FGF2 signaling
We next sought to elucidate the impact of EMT on FGFR1 subcellular localization and signaling capacity. Immunofluorescent staining in combination with confocal microscopy revealed that FGFR1 was localized throughout Twist-expressing NMuMG cells (Fig. 1E) . To delineate the influence of the overall EMT event on this localization profile of FGFR1, NMuMG cells were stably transfected with an FGFR1-eGFP fusion construct and appropriate FGFR1 expression levels were isolated by FACS ( Fig. 2A and Supplementary Fig. S2 ). In contrast to the localization of endogenous FGFR1 that is induced upon Twist-mediated EMT, ectopic expression of FGFR1 predominantly localized at the cell-cell junctions in NMuMG cells ( functional consequence of this change in complex localization is evidenced by the requirement of both β3 integrin and FGFR1 to facilitate enhanced pErk1/2 phosphorylation in response to FGF2 ( Fig. 2D and Supplementary Fig S3A) . These data suggest that through the process of EMT, upregulation of both FGFR1 and β3 integrin are required for BC cells to aberrantly sense FGF2 as a proliferative factor.
Three dimensional cell culture increases expression of β3 integrin and enhances FGF2 signaling
To better recapitulate the in vivo condition we next sought to examine FGF2 signaling under 3D culture conditions. When the NMuMG cells were cultured under 3D growth conditions containing basement membrane extract (BME) FGFR1 overexpression alone, irrespective of β3 integrin expression, was sufficient to facilitate acinar filling in response to exogenous FGF2 (Fig.   3A ). We were able to quantify this FGF2-mediated growth response using bioluminescence (Fig.   3B ). To extend these studies beyond our overexpression systems we utilized the metastatic D2.A1 cells, a system we have recently shown responds poorly to FGF2 when cultured on 2D plastic, but is sensitive to FGFR inhibition in 3D culture and in vivo (23) . Growth of these cells on 2D plastic yields drastically different growth morphologies as compared to 3D culture of the same cells on BME, Fibronectin, or Collagen I (Fig. 3C ). Immunoblot analysis of these differential cultures demonstrated a robust upregulation of β3 integrin in 3D culture conditions as compared to 2D (Fig. 3D) . Consistent with the notion that FGFR1 and β3 integrin are required for aberrant FGF2 signaling, we observed a dramatic increase in FGF2-induced phosphorylation of Erk1/2 when these cells were cultured under 3D conditions as compared to traditional 2D culture conditions (Fig. 3E) . Together with our data from the previous figures these findings suggest that EMT in combination with structural changes in the in vivo growth environment integrin in the D2.A1 cells using previously established and verified shRNAs ( Fig. 4A ; (21)). As previously observed in other models, depletion of β1 integrin led to a robust compensatory increase in the expression of β3 integrin in D2.A1 cells, but this event did not affect the ability of FGF2 to activate Erk1/2 phosphorylation ( Fig. 4A; (21) ). More importantly, directed depletion of β3 integrin in the D2.A1 cells inhibited the ability of FGF2 to stimulate phosphorylation of Erk1/2 ( Fig. 4A; Supplementary Fig. S3B ). To better establish the biological significance of these events, we cultured these cells under 3D growth conditions and quantified cellular outgrowth using bioluminescence (Fig. 4B) . Addition of exogenous FGF2 enhanced the outgrowth of control D2.A1 cells (Fig. 4B and 4C ). As reported previously, depletion of β1 integrin did lead to a robust inhibition of D2.A1 outgrowth (29) . However, this inhibition of basal outgrowth could be completely rescued by the addition of exogenous FGF2, findings that are consistent with the enhanced levels of β3 integrin in these cells ( Fig. 4B and 4C) . Finally, directed depletion of β3 integrin similarly lead to a significant inhibition of basal 3D outgrowth by the D2.A1 cells, but unlike depletion of β1 integrin this event completely prevented the ability of exogenous FGF2 to stimulate the outgrowth of the D2.A1 cells (Fig. 4B and 4C) . 
These data clearly indicate that β3 integrin is necessary for FGF2-mediated 3D outgrowth of metastatic BC cells. 
Pharmacological inhibition of integrin
inhibitors of FAK, PF-562,271/VS-6062 (PF-271) and VS-6063 (Defactinib). Long-term inhibition of FAK using both compounds inhibited FGF2-mediated phosphorylation of Erk1/2 in a dose dependent fashion (Fig. 5B and 5C ). Moreover, a short-term pretreatment (10 minutes) with Defactinib was also highly effective at blocking FGF2-mediated phosphorylation of Erk1/2 (Fig. 5D) . The importance of robust long-term inhibition of FGFR signaling is emphasized by the fact that covalent inhibition of FGFR led to decreased 3D outgrowth following a single dose of inhibitor, results that were not observed with the competitive inhibitor, BGJ-398 (Fig. 5E ).
Defactinib was similarly capable of blocking overall 3D outgrowth after only a single dose of this compound ( Fig. 5E and 5F ). Finally, treatment with Trametinib, an FDA approved allosteric inhibitor of MEK1/2, was similarly capable of inhibiting the 3D outgrowth of the D2.A1 cells and completely blocked the ability of FGF2 to induce outgrowth of our FGFR1 overexpressing NMuMG cells ( Fig. 5E; Supplementary Fig. 5 ). Taken together with our previous findings these data strongly suggest that FAK is functioning downstream of β3 integrin and FGFR1 to facilitate an FGF2:Erk1/2 signaling axis and outgrowth of metastatic BC cells.
Covalent targeting of FGFR blocks metastatic tumor growth
We next sought to specifically evaluate the role of FGFR:β3 signaling in the metastatic tumor microenvironment. We have recently demonstrated that the 4T1 model of advanced stage BC undergoes a spontaneous EMT during in vivo metastasis as compared to the epithelial phenotype of these cells when cultured in vitro (23, 12) . Consistent with these findings, ex vivo RT-PCR analyzes clearly demonstrate that a clonal, luciferase-expressing 4T1 cell line (4T1-L4) displayed robust upregulation of FGFR1 following pulmonary metastasis from the mammary fat pad ( Fig. 6A and Supplementary Fig. S6 ). vivo 4T1-L4 lung metastases demonstrated enhanced expression of β3 integrin, and indicated the upregulation of all the major isoforms of FGFR1 (Fig. 6A) . Along these lines, FIIN-2 and FIIN-4 potently inhibited cellular viability of ex vivo 4T1-L4 pulmonary metastases (Fig. 6B) . In contrast, similar experiments showed no affect of FIIN molecules on cell viability of normal murine mammary gland cells (data not shown). Consistent with these viability data, FIIN-2 and FIIN-4 abrogated the constitutive phosphorylation of Erk1/2 in ex vivo 4T1-L4 pulmonary metastases, even at low nanomolar concentrations (Fig. 6C) . We also specifically monitored organotypic, 3D tumor cell growth within these heterogeneous ex vivo cultures via their stable expression of firefly luciferase, in which treatment with FIIN-2 or FIIN-4 led to a dramatic eradication of tumor cells (Fig. 6D-6E ). To evaluate the in vivo efficacy of FIIN-4, ex-vivo 4T1-L4 pulmonary metastases were re-inoculated into the pulmonary microenvironment of fresh cohorts of mice via a tail vein injection, and pulmonary tumor growth was quantified by bioluminesence (Fig. 6F) . Forty-eight hours after metastatic inoculation, we initiated FIIN-4 therapy via oral gavage. Consistent with our 3D culture data, in vivo FIIN-4 therapy led to a potent inhibition of pulmonary tumor growth (Fig. 6, F and G) . Fifteen days after tail vein inoculation the first control mouse was sacrificed due to pulmonary tumor burden, at which point FIIN-4 treatments were stopped. Even with this discontinuation of therapy, FIIN-4 still resulted in a highly significant prolongation in survival (Supplementary Fig. S7 ). Taken together, these findings clearly demonstrate that FGFR is a major driver of EMT-associated metastatic outgrowth and its function can be successfully antagonized within the metastatic microenvironment through the systemic administration of FIIN-4. To verify the clinical significance of an FGFR:β3 integrin complex in BC progression, we analyzed patient survival rates upon cohort bifurcation based on the mean expression value of FGFR, FAK (PTKB), and β3 Integrin (ITGB3). Analysis of a cohort of basal-like BC patients revealed that β3 integrin expression alone was associated with a significant decrease in patient survival rates, but FAK and FGFR1 alone were not (Fig. 7A) . However, combination of these three genes into a signature led to a more robust separation between high and low expressing tumors ( Fig. 7A; right panel) . FGFR3 or FGFR4 also led to more robust bifurcation in patient survival when combined with β3 integrin and FAK ( Supplementary Fig. S8 ). Consistent with the depletion of FGFR2 through EMT and metastasis, addition of FGFR2 to this signature nullified the ability of β3 integrin to predict for patient survival (Supplementary Fig. S8 ). To further support these data, TNBC brain metastases were harvested from a patient whose disease had progressed while receiving adramycin, taxol, cyclophosphamide (ATC) chemotherapy. These PDX tissues were expanded to 10 individual mice and randomized into two groups 40 days after engraftment. Those mice that received FIIN-4 demonstrated a significant delay in tumor growth as compared to the control group (Fig. 7B ). Taken together with our mechanistic data these findings strongly suggest that EMT-mediated expression of FGFR1 and β3 integrin work in complex through the activity of FAK to drive metastatic tumor growth.
FIIN-4 effectively targets chemotherapy resistant, metastatic TNBC
Discussion:
In the current study we have developed a first-in-class covalent inhibitor of FGFR that is capable of blocking the in vivo growth of TNBC within anatomically relevant metastatic locations.
Mechanistically, we demonstrate that EMT drives the expression of β3 integrin and FGFR1, both of which are necessary for enhanced response to FGF2 ( Fig. 8; (1,28) ). 
recently terminated due to lack of efficacy. Furthermore, systemic inhibition of FAK can inhibit T-cell function, and immune cell infiltration which may detract from its tumor-cell autonomous effects (20, 33) . Due to these reasons the current study did not pursue combination therapies targeting both FAK and FGFR.
Recent findings point to engagement of the extracellular matrix and activation of Erk1/2 signaling as key mechanisms that are required for disseminated BC cells to overcome systemic dormancy and undergo metastatic outgrowth (34, 35) . Our data support and expand upon these findings by demonstrating that FGFR in complex with β3 integrin acts as a key upstream mediator of Erk1/2 activation. Indeed, our data in Figure 3 demonstrate that β3 integrin levels dramatically increase in all 3D culture conditions compared to tissue culture plastic, and this increase was somewhat inhibited by the addition of collagen I. These findings are consistent with the notion that FGFR1:β3 integrin signaling complexes are enhanced in more compliant metastatic microenvironments such as the lungs or liver. Whether the mechanisms of β3 integrin regulation by matrix compliance are related to or independent from the ability of EMT to mediate β3 integrin expression remains to be definitively determined (23) .
Overall our studies herein add important mechanistic understanding to how the processes of EMT drive integrins and growth factor receptors to work in concert during the metastatic progression of BC. Going beyond these mechanistic data we utilized both patient-derived xenografts and a highly aggressive syngeneic model of metastatic BC growing within the pulmonary microenvironment to demonstrate the robust in vivo utility of FIIN-4, a first-in-class covalent inhibitor of FGFR. Finally, we identify a β3 integrin:FAK:FGFR molecular signature that is capable of indicating a poor prognosis group of basal-like BC patients that would clearly 
benefit from FIIN-4 therapy. These findings strongly support the clinical advancement of this exciting therapeutic strategy.
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Members of the Wendt Laboratory are thanked for critical reading of the manuscript. We also thank Dr. David Lum for his assistance in acquiring patient-derived tumor tissues. We also acknowledge the expertise of the personnel within the Purdue Center for Cancer Research Biological Evaluation Core (P30 CA023168). experiments yielding similar results. (C) Metastatic D2.A1 cells were grown on tissue culture plastic or in 3D culture conditions containing basement membrane extract (BME) alone or supplemented with additional Fibronectin or Collagen I as described in the materials and methods. Photomicrographs represent typical growth morphologies of these cells when grown in these various conditions. These brightfield images were collected using a TS100 Nikon microscope at 100x magnification. Representative brightfield photomicrographs of the 3D culture conditions described and quantified in panel B. These images were collected using a TS100 Nikon microscope at 100x magnification. FIIN-2, FIIN-4) , FAK (Defact) or MEK1/2 (Tram) were added for 4 days. Following this treatment period cells were allowed to grow for an additional 4 days and luminescence was quantified. Changes in cellular outgrowth are shown as a percentage relative to the untreated control (CNTRL) luminescence value. Data are the mean values ±SE of at least six replicates completed over at least 2 independent experiments resulting in the indicated P values. (F) Brightfield photomicrographs of final 3D cell clusters formed after the total 12 days of growth. These images were collected using a TS100 Nikon microscope at 100x magnification. In epithelial-like tumor cells FGFR1-iiic levels are low and interactions with E-cadherin limit the ability of FGF2 to stimulate Erk1/2, preventing cell growth. However, following EMT, expression levels of FGFR1-iiic and β3 integrin are increased producing multiple signaling complexes that utilize FAK to aberrantly activate Erk1/2. These molecular events promote metastatic tumor growth, but they also can be used to effectively identify those patients that will respond to FIIN4 therapy, our newly developed covalent inhibitor of FGFR. 
